

Effect of valdecoxib pretreatment on pain and secondary hyperalgesia associated with the heat/capsaicin model in healthy volunteers

Submission date 29/11/2005	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 30/11/2005	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 03/10/2017	Condition category Signs and Symptoms	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Piotr Janicki

Contact details
Penn State Hershey Medical Ctr
Dept. Anesthesiology
H187
500 University Drive
Hershey
United States of America
PA 17036
-
pjanicki@psu.edu

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00260325

Study information

Scientific Title

Effect of valdecoxib pretreatment on pain and secondary hyperalgesia associated with the heat/capsaicin model in healthy volunteers

Study objectives

Selective COX-2 inhibitors significantly attenuate central sensitization and decrease secondary hyperalgesia: a randomised clinical trial

Ethics approval required

Old ethics approval format

Ethics approval(s)

IRB approval at Penn State Hershey Medical Center

Primary study design

Intentional

Study design

Prospective, double blind, randomized, cross-over

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hyperalgesia

Interventions

Administration of single dose 40 mg valdecoxib or placebo orally (PO).
Measurement of heat/cold pain threshold and area of heat/capsaicin-induced hyperalgesia.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

valdecoxib

Primary outcome(s)

Area of secondary hyperalgesia

Key secondary outcome(s)

Pain threshold for cold/heat pain

Completion date

01/01/2006

Eligibility

Key inclusion criteria

Healthy volunteers, both genders

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Pregnancy, known allergy to COX-2 inhibitors, current infection or treatment with analgesics

Date of first enrolment

01/01/2004

Date of final enrolment

01/01/2006

Locations**Countries of recruitment**

United States of America

Study participating centre

Penn State Hershey Medical Ctr

Dept. Anesthesiology

Hershey

United States of America

PA 17036

Sponsor information**Organisation**

Pfizer Inc. (USA)

ROR

<https://ror.org/01xdqrp08>

Funder(s)

Funder type

Industry

Funder Name

Independent Investigator Grant from Pfizer Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	10/03/2006		Yes	No